Those who thought the Drug Enforcement Administration (DEA) composed the deck of cannabis passage favoring prohibitionists under the Joe Biden administration may be in for more disappointment.

Under a new hearing process set to begin June 29 before an administrative law judge — for the DEA to determine the merits of a proposed rule reclassifying cannabis as a Schedule III drug under the Controlled Substances Act (CSA) — President Donald Trump’s administration will only accept testimony from those who oppose the proposed rule.

On June 18, the DEA announced seven “interested persons” who were “affected or affected” by the proposed rule, all of whom oppose loosening federal restrictions on cannabis. Among the seven appointed participants are:

1. National Drug and Alcohol Screening Association (NDASA)
2. Tennessee Bureau of Investigation
3. Smart Approaches to Marijuana (SAM)
4. The states of Nebraska, Idaho, Indiana and Louisiana
5. Two voices of the victim
6. Kenneth Finn, MD
7. Philip A. Drum, Pharm.D.

To read the rest of this article on Cannabis Business Times, Click here